InnoCare Pharma has announced the completion of subject enrolment in the Phase II clinical trial of ICP-488, a treatment designed for individuals with moderate to severe plaque psoriasis.

This marks a significant milestone in the development of the drug, which is a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor.

The randomised, multi-centre, double-blind, placebo-controlled trial aims to assess the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in adult Chinese patients.

A total of 129 moderate to severe plaque psoriasis patients were enrolled in the study.

Participants in the trial were randomly assigned to one of three groups in equal proportions to receive either a 6mg or 9mg once-daily ICP-488 or a placebo.

They will undergo treatment for 12 consecutive weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ICP-488 has previously shown promising efficacy and safety results in a Phase I trial for treating psoriasis.

InnoCare co-founder, chairwoman and CEO Dr Jasmine Cui said: “Psoriasis requires long-term management, and there is still a significant unmet demand for new drugs, especially oral medications in its treatment.

“We are very pleased to see the completion of patient enrollment in the phase II clinical trial for the treatment of psoriasis with ICP-488. We remain committed to diligently advancing the clinical development of this promising therapy, with the goal of providing improved treatment options to psoriasis patients as soon as possible.”

In March, the company dosed the first patient in a Phase Ib trial to investigate the combination of ICP-189 and ArriVent BioPharma’s furmonertinib in treating non-small cell lung cancer.